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Faster fibrin clot degradation 
characterizes patients with central 
pulmonary embolism at a low risk 
of recurrent peripheral embolism
Robert W. Kupis1, Sarah Goldman-Mazur1, Maciej Polak2, Michał Ząbczyk1 & Anetta Undas1,3
It is unclear whether thrombus location in pulmonary arteries is associated with particular clot 
characteristics. We assessed 156 patients following either central or peripheral pulmonary embolism 
(PE). Plasma clot lysis time, the rate of D-dimer release from plasma clots (D-Drate) with the maximum 
D-dimer concentration achieved (D-Dmax), as well as fibrin formation on turbidimetry, plasma clot 
permeation, thrombin generation, and fibrinolytic parameters were measured 3–6 months after PE. 
Patients following central PE (n = 108, 69.3%) were more likely smokers (38.9% vs 18.8%; p = 0.01), less 
likely carriers of factor XIII Val34Leu allele (40.7% vs 62.5%, p = 0.01), exhibited 16.7% higher D-Drate 
and 12.7% higher tissue plasminogen activator antigen (tPA:Ag) compared with peripheral PE (p = 0.02 
and p < 0.0001, respectively). Saddle PE patients (n = 31, 19.9%) had 11.1% higher D-Drate and 7.3% 
higher D-Dmax compared with central PE (both p < 0.05). Twenty-three recurrent PE episodes, including 
15 central episodes, during a median follow-up of 52.5 months were recorded. Plasma D-dimer and 
tPA:Ag were independent predictors for central recurrent PE, whereas D-Drate and peak thrombin 
predicted peripheral recurrent PE. Plasma clots degradation is faster in patients following central PE 
compared with peripheral PE and fibrinolysis markers might help to predict a type of recurrent PE.
Pulmonary embolism (PE) is a life-threatening disease which affects approximately 50 to 70 per 100 000 annually 1  
and causes more than 300 000 deaths in Europe per year2. PE can be classified either as central, when thrombus is 
located in the trunk or in the main pulmonary arteries, or peripheral, when it is seen in segmental or subsegmental 
arteries. Central arteries are most commonly involved3. The saddle PE, a thrombus straddling the bifurcation 
of the main pulmonary artery trunk, is found in 2–5% of all patients with PE4 and the short-term mortality in 
such patients is estimated at 4.3%, while the overall risk of death in all PE cases is estimated at 5.4%5. Factors that 
determine the location of embolic material in PE are largely unknown.
The last step of coagulation is the conversion of fibrinogen into insoluble fibrin, stabilized by active factor XIII. 
Fibrin properties determined by genetic and environmental factors6,7 including cigarette smoking or obesity8, 
can be unfavourably altered which in most cases denotes faster formation of compact fibre networks and relative 
resistance to plasmin. The prothrombotic clot phenotype has been shown in patients with a history of unprovoked 
venous thromboembolism (VTE), including those with PE and deep vein thrombosis (DVT)9. On the other hand, 
it has been demonstrated that clot lysis time (CLT) in acute PE is shorter, which correlates with lower clot den-
sity10, whereas residual pulmonary perfusion defects after acute PE were associated with longer CLT11. Recently, 
we have reported that the prothrombotic plasma clot phenotype, involving reduced permeation coefficient (Ks) 
and reduced maximum rate of increase in D-dimer levels in the lysis assay (D-Drate), assessed a few months since 
the index event, is a risk factor for PE recurrences12.
It is unknown whether plasma clot properties differ with regard to the location of thrombotic material in 
pulmonary arteries. In central PE, it has been shown that the architecture of a surgically removed embolus 
depends on the location in pulmonary vasculature, with more tightly packed fibrin fibres in segmental pulmonary 
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vessels13,14. The compaction of peripheral emboli may in part explain its resistance to endogenous fibrinolysis15. 
We hypothesized that plasma fibrin clots, which are degraded by fibrinolytic enzymes at a higher rate in specific 
assays, characterize patients with central PE. As a result, larger parts of thrombus could break off more easily, and 
might travel to the pulmonary arteries, where they would be lodged in larger calibre vessels.
Material and Methods
Patients. We investigated 156 consecutive patients aged 18–65 years with a history of documented first-ever 
PE episode referred to an outpatient clinic for thrombophilia screening or further laboratory work-up since June 
2009 to March 2012. The inclusion and exclusion criteria were presented in detail previously12. Briefly, PE treated 
with thrombolysis or pulmonary embolectomy, known malignancy, end-stage renal insufficiency, liver injury, 
severe thrombophilia and ongoing anticoagulant treatment were the exclusion criteria. The diagnosis of DVT was 
based on positive colour duplex sonography findings. Based on the results of the high resolution spiral computed 
tomography, at least 64-row multidetector scanner, central PE was diagnosed when thrombi was located in the 
pulmonary trunk or/and in one of the main pulmonary arteries on the left or right side. Peripheral PE was diag-
nosed only when the thrombus was visualised in either segmental or subsegmental pulmonary arteries.
Vitamin K antagonists were started during the first week after the first-ever episode of PE, and continued for 
at least 3 months in cases of VTE that was triggered by short-term risk factors, or for at least 6 months in patients 
with VTE of unknown origin, based on the physicians’ decision.
The Jagiellonian University Ethical Committee approved the study and all patients gave the informed consent 
in accordance with the Declaration of Helsinki. All further methods and investigations were performed according 
to the newest and known guidelines and regulations.
Laboratory investigations. Blood samples were drawn from an antecubital vein with minimal stasis using 
atraumatic and rapid venepuncture with at 8 to 10 AM following anticoagulation withdrawal. Citrate collec-
tion tubes were used. Lipid profiles, blood cell count, glucose, creatinine, and international normalized ratio 
(INR) were assayed by routine laboratory techniques. Fibrinogen was determined using the Clauss method. 
High-sensitivity C-reactive protein (CRP) was measured by nephelometry (Siemens, Marburg, Germany). Plasma 
D-dimer, tissue-type plasminogen activator (tPA:Ag) and plasminogen activator inhibitor-1 (PAI-1:Ag) antigens 
(all, American Diagnostica, Greewich, CT) were determined by immunoenzymatic assays. Factor V Leiden (FV 
Leiden), prothrombin 20210 A, FXIII Val34Leu and α-fibrinogen Thr312Ala polymorphisms were determined 
by the polymerase chain reaction followed by restriction fragment length polymorphism analysis, as previously 
described9. All measurements were performed by technicians blinded to the origin of the samples. Intra-assay and 
inter-assay coefficients of variation were 5–7%.
Fibrin clot analysis involving plasma clot permeability, turbidimetric assessment of clot formation and clot 
lysis at 2 various concentrations of recombinant tPA (rtPA) were performed in all PE patients as previously 
described12.
Briefly, the permeability of fibrin clot was determined using a pressure-driven system9,16. Tubes containing 
fibrin clots were connected through plastic tubing to a buffer reservoir, and the volume flowing through the gel 
was measured. The permeation coefficient (Ks) was calculated from a formula:
= ΔµK QxLx /txAx p,s
where Q is the flow rate in time t; L, the length of a fibrin gel; µ, the viscosity of liquid (in poise); A, the 
cross-sectional area (in cm2) and Δp, a differential pressure (in dyne/cm2)12.
Plasma citrated samples were mixed 2:1 with a Tris buffer, containing 0.6 U/mL human thrombin (Sigma) and 
50 mM calcium chloride, which initiated polymerization9,17. Absorbance was read at 405 nm. The lag phase of the 
turbidity curve, which reflects the time required for initial protofibril formation and maximum absorbance at the 
plateau phase (ΔAbmax), indicating the number of protofibrils per fibre, were recorded16,18.
Efficiency of clot lysis was determined using 2 assays. In the first assay, CLT was measured as described19,20. 
Briefly, citrated plasma was mixed with 15 mM calcium chloride, 6 pM human tissue factor (Innovin, Siemens), 
12 μM phospholipid vesicles and 14 µM recombinant tPA (rtPA, Boehringer Ingelheim, Germany). The mixture 
was transferred to a microtiter plate and its turbidity was measured at 405 nm at 37 °C. CLT was defined as the 
time from the midpoint of the clear-to-maximum-turbid transition, which represents clot formation, to the mid-
point of the maximum-turbid-to-clear transition (representing the lysis of the clot). In the second assay, fibrin 
clots, formed as for the permeation evaluation were perfused with Tris buffer containing 0.2 µM rtPA and released 
D-dimer levels were measured in the effluent. D-dimer levels were measured every 30 minutes in the effluent. The 
experiment was stopped, usually after 90 to 120 min, while the fibrin gel collapsed under the pressure. D-Drate and 
maximum D-dimer concentrations (D-Dmax) were analysed as described9,16,21.
Thrombin generation was assessed using the Calibrated Automated Thrombogram22. Briefly, 80 μl of thawed 
platelet poor plasma was mixed with 20 μl of a reagent containing recombinant relipidated tissue factor and phos-
pholipids, with the final concentrations of 5 pM and 4 mM, respectively. Thrombin specific fluorogenic substrate 
was added. The fluorescence intensity was recorded by the Fluoroskan Ascent® microplate fluorometer (Thermo 
Fisher Scientific Oy, Vantaa, Finland) using the software program (Thrombinoscope BV, version 3.0.0.29). Three 
variables were analysed: “peak thrombin” (nM), i.e. the maximum concentration of thrombin formed during the 
registration time; the “endogenous thrombin potential” (ETP, nM × min), i.e. the area under the curve showing 
thrombin formation, and “time to thrombin peak” (s), i.e. the time from start of thrombin generation till the 
maximum thrombin value.
Follow-up. We contacted all patients at least twice a year through clinic visits or by telephone. We used a 
confirmed symptomatic PE as the primary study endpoint. Secondary endpoints were all-cause death and DVT 
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alone. Data were censored at the time of PE or DVT during follow-up. The spiral CT and pulmonary angiography 
were performed when recurrent PE was suspected. The colour duplex sonography was performed in every subject 
with signs or symptoms suggestive of DVT. VTE was considered as recurrent only if PE and/or DVT occurred 
after a successful acute treatment of the initial episode.
Statistical analysis. The study was powered to have a 80% chance of detecting a 0.6 standardized mean dif-
ference in D-Drate using a P-value of 0.05, based on the values from a published article23. In order to demonstrate 
such a difference or greater, 46 patients or more were required in each group. Data are expressed as mean and 
standard deviation (SD) or median (interquartile range, IQR) as appropriate. The Shapiro-Wilk test was used to 
assess conformity with a normal distribution. The continuous variables were compared between two groups using 
Student’s t test for independent groups for mean values and Mann-Whitney U test for distribution. Categorical 
variables were analysed using the χ2 test or Fisher’s exact test as appropriate. Predictors of central or peripheral 
recurrent PE episode were identified in the binominal logistic regression analysis (variables with p < 0.1 in the 
univariable analysis entered the respective multiple model). A strong correlation between any two parameters 
(r > 0.5) excluded one of the parameters from the multiple logistic regression models, except for fibrinogen, 
which was included as a key confounder. The final logistic regression model was adjusted for age, sex, BMI and 
fibrinogen. In the bivariate analysis all factors were adjusted for fibrinogen level separately. The Pearson’s corre-
lation coefficient or Spearman’s rank correlation coefficient were calculated to assess correlations as appropri-
ate. Two-sided P-values < 0.05 were considered statistically significant. Analysis was performed using SPSS 23.0 
(SPSS Inc., Chicago, IL, USA).
Results
A total of 156 patients were studied (Table 1). Initial central PE was observed in 108 cases (69.3%) including 31 
patients with saddle PE (19.9%). Among 48 patients with peripheral PE (30.7%), 26 subjects had segmental PE 
(16.7%) and 22 patients had subsegmental PE (14.1%, Supplemental Table 1).
Demographic and clinical parameters were similar in all groups, except for a higher prevalence of cigarette 
smokers in patients after central PE compared with the remainder (Table 1). In terms of routine laboratory inves-
tigations, fibrinogen was 15.6% lower in patients with central PE compared with peripheral PE (Table 1). No other 
intergroup differences in other laboratory parameters were observed.
Duration of anticoagulation treatment following the first episode of PE ranged from 4 to 20 months (median 
10.5 months, Table 1). As shown in Table 1, factor XIII Val34Leu allele was found in 74 patients, and lower 
prevalence was found in the central PE group compared with those following subsegmental and subsegmental 
PE (p = 0.009 and p = 0.025, respectively). α-fibrinogen Thr312Ala, factor V Leiden and prothrombin 20210 A 
mutation were distributed similarly. No differences in genetic polymorphisms between patients with saddle PE 
and other types of central PE were observed (Supplemental Table 1).
Fibrin variables. Fibrin clot variables showed no differences among patients after the index central versus 
peripheral PE with the only exception. As shown in Fig. 1, after adjustment for fibrinogen, D-Drate was 16.7% 
higher in the central PE group than in the peripheral PE group, including individuals with segmental and subseg-
mental episodes (by 15.4% and by 13.6%, respectively).
When patients with saddle PE were compared with other subjects with central PE, we found that, after adjust-
ment for fibrinogen, D-Drate was 11.1% higher and D-Dmax 7.3% higher compared with the latter group (Fig. 2, 
panel A and B; Supplemental Table 1). No other intergroup differences in fibrin clot properties were observed.
Moreover, tPA:Ag was higher in patients with central PE compared with patients with peripheral (p = 0.006) 
and both segmental and subsegmental PE (by 12.9% and by 10.6%, p = 0.02; Table 2). Saddle PE patients showed 
16.7% higher tPA:Ag than other central PE (Supplemental Table 2). In the central PE group D-Drate correlated pos-
itively with D-Dmax (r = 0.2, p = 0.03) and tPA:Ag (r = 0.28, p = 0.003), whereas in the peripheral PE D-Drate was 
positively associated solely with tPA:Ag (r = 0.23, p = 0.003). There were no intergroup differences in PAI-1:Ag.
There were no differences in thrombin generation profiles, including time to peak, peak thrombin and ETP, 
between central and peripheral PE. The same held true for individuals with saddle PF versus other central PE 
(Table 2, Supplemental Table 2).
Smokers exhibited 3.6% lower ΔAbmax than non-smokers, while Ks was 4% higher in smokers than 
non-smokers (Supplemental Table 3). No other differences in fibrin clot variables between the smoking and 
non-smoking groups were observed.
Patients with FXIII Val34Leu allele exhibited lower Ks (median, [IQR]; 6.0 [1.6] 10−9 cm2 vs 7.45 [1.3] 10−9 
cm2, respectively, p = 0.016) and higher ΔAbmax (median, [IQR]; 0.85 [0.11] 405 nm vs 0.81 [0.8] 450 nm, respec-
tively, p = 0.005) compared with the non-carriers. Moreover, tPA:Ag was lower in the 34 Leu carriers group 
(median, [IQR]; 9.1 [4.0] ng/mL vs 10.2 [3.6] ng/mL, respectively, p = 0.008). No other intergroup differences 
related to genetic polymorphisms were observed.
Follow-Up. The median follow-up was 52.5 months (range 2 to 70 months). Five (3.2%) patients were lost to 
follow-up. Twenty-three (14.7%) recurrent PE episodes were recorded. In 15 (65.2%) patients central recurrent 
PE episode was reported, including 7 (30.4%) saddle PE episodes). There were 5 (21.7%) segmental and 3 (13.0%) 
subsegmental recurrent PE episodes. Median time from the first PE episode to the recurrent PE episode was 16 
months (IQR, 14 months). Seven (4.5%) patients died, including 2 patients who experienced recurrent PE (one 
central and one segmental).
No differences in demographic and laboratory parameters were observed in patients with recurrent cen-
tral versus peripheral PE (Supplemental Table 4). No differences were shown in regard to fibrin clot features, 
www.nature.com/scientificreports/
4SCIEnTIfIC REPORts |            (2019) 9:72  | DOI:10.1038/s41598-018-37114-4
thrombotic and fibrinolysis markers compared peripheral with no-saddle central recurrent PE, including no 
differences in either D-Drate or D-Dmax (Supplemental Table 5).
Multinominal multivariate logistic regression adjusted for sex, age, BMI and fibrinogen showed that plasma 
D-dimer and tPA:Ag were predictors for central recurrent PE, whereas D-Drate and peak thrombin predicted 
peripheral recurrent PE (Table 3). Every 0.01 mg/L/min increase in D-Drate was associated with lower risk of 
peripheral PE (OR 0.09; 95% CI, 0.01–0.66; p = 0.02), whereas every 100 ng/ml increase in plasma D-dimer 
was predictive of central recurrent PE (OR, 1.006; 95% CI, 1.002–1.010; p = 0.001; Table 3). Similar results were 
observed in bivariate multinominal regression built independently for each factor with adjustment for fibrinogen 
(Supplemental Table 6).
Discussion
To our knowledge, this study is the first to evaluate associations between plasma fibrin clot properties and the PE 
location with long-term follow-up. We demonstrated that patients with central PE display higher rate of fibrin clot 
degradation, reflected by increased D-Drate, compared with peripheral PE. The difference in the rate of fibrinolysis 
was even more pronounced, when saddle PE patients were compared with those with other central PE episodes. 
Moreover, higher D-Drate is associated with lower risk of recurrent peripheral PE. This study suggests that there is 
a persistent tendency to faster fragmentation of solid preformed fibrin, measurable in a plasma-based assay 3–6 
months after the index PE event that can be observed in subjects who experienced central PE. Our study suggests 
that there are some individual differences in clot lysability that may distinguish different PE forms and some 










Peripheral (n = 48)
p-value#  
(A vs C vs D)
C Segmental 
PE (n = 26)
D Subsegmental 
PE (n = 22)
Age, years 44 ± 13 45 ± 12 41.08 ± 13.51 0.10 40 ± 15 43 ± 12 0.26
Male, n (%) 82 (52.6) 59 (54.6) 23 (47.9) 0.40 9 (34.6) 14 (64.0) 1.0
BMI, kg/m2 26.2 ± 4.3 25.89 ± 4.17 26.88 ± 4.53 0.29 27.07 ± 3.65 26.65 ± 5.46 0.31
Clinical characteristics
Current Smoking, n (%) 51 (32.7) 42 (38.9) 9 (18.8) 0.01 7 (26.9) 2 (9.1) 0.02
Heart failure, n (%) 6 (3.8) 3 (2.8) 3 (6.3) 0.3 0 (0.0) 3 (14.0) 0.03
COPD, n (%) 6 (3.8) 5 (4.6) 1 (2.1) 0.4 0 (0.0) 1 (5.0) 0.54
Trauma/Surgery, n (%) 36 (23.1) 27 (25.0) 9 (18.8) 0.4 5 (19.0) 4 (18.0) 0.69
Pregnancy*, n (%) 10 (13.5) 5 (10.2) 5 (20.0) 0.2 3 (18.0) 2 (25.0) 0.37
Family history of VTE, n (%) 27 (17.3) 15 (13.9) 12 (25.0) 0.09 4 (15.0) 8 (36.0) 0.04
Oral Contraceptives*, n (%) 8 (12.2) 8 (10.8) 0 (0) 0.19 0 (0) 1 (20) 0.34
Unprovoked VTE, n (%) 89 (57.0) 60 (55.6) 29 (60.4) 0.6 16 (62.0) 13 (59.0) 0.84
Concomitant DVT, n (%) 53 (34.0) 33 (30.6) 20 (41.7) 0.2 11 (42.0) 9 (41.0) 0.40
Time of anticoagulation, months 10.6 ± 3.7 10.68 ± 3.67 10.42 ± 3.76 0.69 11.12 ± 4.37 9.59 ± 2.77 0.45
Laboratory parameters
Creatinine, μmol/l 73.42 (12.4) 73.52 (13.4) 73.20 (9.9) 0.88 71.09 (10.5) 75.70 (8.6) 0.34
Glucose, mmol/l 5.04 (0.8) 4.98 (0.9) 5.0 (0.7) 0.77 5.05 (0.8) 5.00 (0.6) 0.70
TG, mmol/L 1.26 (0.8) 1.12 (0.7) 1.1 (0.8) 0.95 1.10 (1.0) 1.20 (0.7) 0.94
TC, mmol/l 5.09 (1.1) 5.16 (1.1) 4.92 (1.2) 0.21 4.93 (1.2) 3.04 (0.9) 0.36
HDL-C, mmol/l 1.49 (0.4) 1.48 (0.4) 1.49 (0.4) 0.92 1.50 (0.4) 4.90 (1.2) 0.87
LDL-C, mmol/l 3.14 (1.0) 3.21 (1.0) 3.00 (1.0) 0.24 2.98 (1.1) 1.48 (0.4) 0.26
hsCRP, mg/L 1.56 (1.6) 1.49 (1.3) 1.7 (1.0) 0.12 1.82 (1.3) 1.58 (0.7) 0.28
INR 0.98 (0.1) 0.98 (0.1) 0.97 (0.1) 0.66 0.98 (0.1) 0.97 (0.1) 0.91
D-dimer, ng/ml 295 (129) 297 (112) 293 (145) 0.82 302 (136) 283 (158) 0.65
Fibrinogen, g/l 3.1 (1.4) 2.98 (1.2) 3.5 (1.3) 0.03 3.41 (1.3) 3.70 (1.3) 0.09
Genetic polymorphisms, n (%)
α-fibrinogen Thr312Ala allele carriers 52 (33.3) 34 (31.5) 18 (37.5) 0.5 6 (23.1) 12 (54.5) 0.054
Factor V Leiden mutation 14 (9.0) 12 (11.1) 2 (4.2) 0.16 0 (0.0) 2 (9.1) 0.21
Prothrombin 20210 A mutation 6 (3.8) 4 (3.70) 2 (4.2) 0.89 1 (3.8) 1 (4.5) 0.98
Factor XIII Val34Leu allele carriers 74 (47.4) 44 (40.7) 30 (62.5) 0.01 18 (69.5) 12 (54.5) 0.03
Table 1. Baseline characteristics of the studied groups. Data are shown as mean (standard deviation), median 
(interquartile range) or number (percentage). BMI, body mass index, COPD, chronic obstructive pulmonary 
disease; DVT, deep vein thrombosis; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity 
C-reactive protein; INR. international normalized ratio; LDL-C, low-density lipoprotein cholesterol; PE, 
pulmonary embolism; TC, total cholesterol; TG, triglycerides and VTE, venous thromboembolism. #p- values 
refer to Kruskal-Wallis ANOVA test. *Females only.
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From a methodological point of view, we found that a single lysis assay is able to differentiate between patients 
with central or peripheral PE when tested after the event. This assay determines the rate of rtPA-induced deg-
radation of the previously prepared plasma clots (using thrombin and calcium added to citrated plasma) by 
Figure 1. Comparison of maximum rate of increase in D-dimer levels in the lysis assay (D-Drate) between 
patients with central pulmonary embolism (PE) and peripheral PE.
Figure 2. Comparison of maximum rate of increase in D-dimer levels in the lysis assay (D-Drate, panel A) and 
maximum D-dimer levels in the lysis assay (D-Dmax, panel B) between group with saddle pulmonary embolism 
(PE) vs group with other central PE.
Variable Total (n = 156)






Peripheral (n = 48)
p-value  
(A vs C vs D)
C Segmental PE 
(n = 26)
D Subsegmental 
PE (n = 22)
Lag phase, s 41.84 (5.1) 41.69 (5.1) 42.19 (5.3) 0.57 42.38 (5.6) 41.95 (5.2) 0.76
ΔAbmax, 405 nm 0.83 (0.1) 0.82 (0.1) 0.84 (0.1) 0.12 0.85 (0.1) 0.84 (0.1) 0.23
Ks, 10−9 cm2 7.24 (1.1) 7.32 (1.1) 7.07 (1.2) 0.19 7.07 (1.2) 7.07 (1.2) 0.42
D-Dmax, mg/L 4.14 (0.5) 4.17 (0.5) 4.07 (0.6) 0.24 4.04 (0.6) 4.09 (0.6) 0.30
D-Drate, mg/L/minǂ 0.072 (0.011) 0.075 (0.009) 0.065 (0.0065) <0.0001 0.065 (0.005) 0.066 (0.008) <0.0001
CLT, min 87.89 (16.2) 87.94 (16.9) 87.8 (14.7) 0.95 89.23 (14.2) 86.05 (15.4) 0.74
Time to peak, s 310.5 (142.5) 307.00 (132.0) 315.50 (150.5) 0.39 326.50 (119.0) 285.00 (187.0) 0.32
Peak thromin, nM 240.41 (84.2) 241.00 (83.8) 239.50 (90.8) 0.67 237.00 (79.0) 269.50 (132.6) 0.40
ETP, nM × min 1578.3 (92.7) 1576.6 (93.6) 1582.3 (91.3) 0.72 1564.19 (89.7) 1603.64 (90.5) 0.40
tPA:Ag, ng/mL 9.83 (2.8) 10.21 (2.7) 9.0 (2.9) 0.006 8.89 (2.8) 9.13 (3.0) 0.02
PAI-1:Ag, ng/mlǂ 12.9 (7.34) 12.90 (7.25) 12.0 (7.22) 0.56 12.10 (6.7) 11.50 (6.5) 0.69
Table 2. Comparison of fibrin clot features, thrombotic and fibrinolysis markers in the studied groups. Data are 
shown as median (interquartile range). ΔAbmax, maximum absorbance on turbidimetry; CLT, clot lysis time; 
D-Dmax, maximum D-dimer levels in the lysis assay; D-Drate, maximum rate of increase in D-dimer levels in the 
lysis assay; ETP, endogenous thrombin potential; Ks, fibrin clot permeability coefficient; PAI-1:Ag, plasminogen 
activator inhibitor-1 antigen; peak thrombin, peak thrombin concentration; time to peak, time to peak 
thrombin generation; tPA:Ag, tissue plasminogen activator antigen. ǂAdjusted for fibrinogen.
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evaluating D-Drate. However, differences in fibrinolysis between those two subgroups were absent while using 
CLT in which a much lower rtPA concentration is applied together with phospholipids and tissue factor. This 
discrepancy between results of those two assays has been observed previously in a few disease states23,24. It might 
be speculated that fibrinolysis as a complex closely regulated process cannot be assessed for clinical purposes in 
different conditions using one assay. One assay, like one size, does not fit all. Interestingly, in the context of PE, the 
assay describing the degradation of fibrin clot at higher rtPA concentrations in the buffer allows to detect indi-
viduals prone to develop central PE, in particular the saddle PE. Of note, the assay in which D-Drate or D-Dmax are 
evaluated, resembles the situation, in which already existing clots in veins and/or pulmonary arteries are exposed 
to exogenous tPA during fibrinolytic therapy. The concentrations of rtPA used in this assay are similar to those 
encountered during thrombolysis25.
In our study a larger prevalence of smokers in patients following central PE is an intriguing finding. Smoking 
has been reported to be an independent risk factor of reduced long-term survival in VTE patients26. To our 
knowledge, no differences in PE location in regard to smoking have been reported in the literature. It is worth 
noting that current smoking may unfavourably alter clot properties with the greatest impact observed in heavy 
smokers27. Moreover, smoking cessation results in improved fibrin clot properties, reflected by less dense fibrin 
network with wider branching angles between fibres27.
A higher prevalence of FXIII Val34Leu allele carriers among subjects with peripheral PE deserves a com-
ment. FXIII 34Leu allele has been reported to be associated with lower clot permeation and turbidity compared 
to 34Val28, which is consistent with our study. A protective role of 34Leu in thromboembolism is supported by 
few studies29. The unexpected association between PE location and these polymorphisms is a novel finding with 
deserves further investigation.
We observed that higher D-Drate is associated with lower risk of recurrent peripheral PE. Previous studies done 
by our group have shown that prothrombotic clot phenotype is associated with higher risk of recurrent VTE and 
PE events12,30. The decision how long the treatment should last in PE patients is made in most cases in a individ-
ual manner taking into account patient risks and benefits. Usually, the treatment lasts 3–6 months, however, for 
unprovoked PE extended time of treatment seems to be beneficial31. Our finding suggest that patients with unfa-
vourable clot properties after provoked or unprovoked PE should be under closer surveillance if they discontinue 
anticoagulation. It is possible that patients with prothrombotic clot phenotype could benefit from longer antico-
agulation to prevent PE recurrences. Given intensive efforts to standardize fibrin clot measurements, we believe 
that the diagnostic potential of these new markers is substantial, however, further work on implementation of 
such measurements in practice are needed.
This study has several limitations. Firstly, the size of the recurrent PE group was small, but similar to values 
reported in other studies11. It is unknown whether the results obtained 3–6 months after the event could have 
been observed during acute PE, because there was no data about fibrin clot properties measured at the time of 
diagnosis. We cannot extrapolate our findings to the high-risk or elderly PE patients who were ineligible in this 
study. Secondly, blood samples were drawn only once; therefore, we cannot exclude changes in fibrin clot prop-
erties over time. Plasminogen or plasma factor XIII levels were not measured. Oligo- or asymptomatic recurrent 
PE or DVT could have been overlooked and the PE recurrences might have been underrepresented. Finally, since 
clot properties are affected by a number of factors, other potential modulators of plasma fibrin clot structure and 
function following the first PE episode might also be important, and they should be investigated in the future.
In conclusion, our study showed that the rate of clot degradation at concentrations of rtPA similar to those 
during thrombolysis is enhanced in patients with central PE and decreases when the pulmonary artery calibre 
reduces. D-Drate might help to predict form of recurrent PE episodes.
Variable
Central PE recurrence Peripheral PE recurrence
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Age 1.02 (0.97–1.06) 0.48 1.02 (0.97–1.07) 0.53 1.03 (0.97–1.09) 0.40 1.04 (0.97–1.12) 0.28
Male sex 1.88 (0.63–5.59) 0.26 3.22 (0.79–13.14) 0.10 3.76 (0.73–19.33) 0.11 5.97 (0.69–51.60) 0.10
BMI 0.99 (0.87–1.12) 0.87 0.93 (0.78–1.12) 0.46 1.02 (0.86–1.20) 0.84 0.93 (0.75–1.17) 0.54
Fibrinogen 0.47 (0.22–0.99) 0.047 0.27 (0.09–0.78) 0.016 0.93 (0.42–2.06) 0.86 0.51 (0.16–1.59) 0.24
D-dimer 1.005 (1.002–1.008) 0.002 1.006 (1.002–1.010) 0.001 1.003 (0.999–1.007) 0.1 1.002 (0.997–1.006) 0.44
Ks 0.92 (0.56–1.50) 0.7 — — 0.54 (0.26–1.10) 0.09 — —
D-Dmax 0.84 (0.29–2.44) 0.74 — — 0.84 (0.20–3.52) 0.81 — —
D-Drate 0.55 (0.26–1.18) 0.12 0.57 (0.19–1.67) 0.30 0.21 (0.06–0.74) 0.02 0.09 (0.01–0.66) 0.02
peak thrombin 1.003 (0.996–1.011) 0.4 1.003 (0.993–1.014) 0.55 1.012 (1.004–1.020) 0.003 1.016 (1.005–1.027) 0.004
ETP 1.001 (0.995–1.007) 0.8 — — 1.008 (0.999–1.017) 0.07 — —
tPA:Ag 0.78 (0.62–0.98) 0.03 0.70 (0.51–0.96) 0.03 0.96 (0.74–1.25) 0.78 0.77 (0.52–1.15) 0.20
Table 3. Multinominal logistic regression model for central or peripheral recurrent PE episode in relation to 
recurrence-free patients. The final model was adjusted for: age, sex, BMI and fibrinogen. BMI, body mass index; 
ETP, endogenous thrombin potential; D-Dmax, maximum D-dimer levels in the lysis assay; D-Drate, maximum 
rate of increase in D-dimer levels in the lysis assay; ETP, endogenous thrombin potential; Ks, fibrin clot 
permeability coefficient; peak thrombin, peak thrombin concentration; tPA:Ag, tissue plasminogen activator 
antigen.
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